1. Comparison and interpretability of the available urticaria activity scores. Issue 1 (18th September 2017) Authors: Hawro, T.; Ohanyan, T.; Schoepke, N.; Metz, M.; Peveling‐Oberhag, A.; Staubach, P.; Maurer, M.; Weller, K. Journal: Allergy Issue: Volume 73:Issue 1(2018) Page Start: 251 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Development of tripe palms and soles in a patient with long pre‐existing systemic mastocytosis and newly developed non‐small cell lung cancer. (7th November 2017) Authors: Bonnekoh, H.; Ohanyan, T.; Lenze, D.; Krause, K.; Maurer, M.; Zuberbier, T.; Siebenhaar, F. Journal: Journal of the European Academy of Dermatology and Venereology Issue: Volume 32:Number 4(2018) Page Start: e151 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Increased angiogenesis and VEGF expression correlates with disease severity in prurigo patients. (7th October 2015) Authors: Krull, C.; Schoepke, N.; Ohanyan, T.; Brachaczek, M.; Maurer, M.; Lange‐Asschenfeldt, B.; Metz, M. Journal: Journal of the European Academy of Dermatology and Venereology Issue: Volume 30:Number 8(2016:Aug.) Page Start: 1357 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Omalizumab may not inhibit mast cell and basophil activation in vitro. (26th September 2014) Authors: Gericke, J.; Ohanyan, T.; Church, M.K.; Maurer, M.; Metz, M. Journal: Journal of the European Academy of Dermatology and Venereology Issue: Volume 29:Number 9(2015:Sep.) Page Start: 1832 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗